International
The Morning Science

What science found today

‹
 

Research

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

PLOS ·

The Brief

  • BRAFV600E mutations drive constitutive MAPK signaling across various cancers.
  • Resistance to MEK inhibitors such as trametinib undermines their clinical benefit.
  • The study reports that GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma.

Why it matters

The study identifies a signaling pathway that can sustain MAPK activity despite MEK inhibition, which may point to ways of overcoming treatment resistance in BRAF-mutant melanoma.

Who’s affected

  • cancer researchers studying melanoma and MAPK pathway inhibitors

by Jingyi Ke, Zi Wang, Zhengyang Guo, Guangshuo Ou, Wei Li Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhibitors such as trametinib undermines clinical benefits, and the mechanisms sustaining MAPK activity…

Timeline

  1. Study published in PLOS Genetics

  2. PLOS Genetics

    GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

How do you feel about this?

0 Comments

    GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma – The Morning Science